HRP20151006T1 - Terapeutska uporaba diaminofenotiazina - Google Patents
Terapeutska uporaba diaminofenotiazina Download PDFInfo
- Publication number
- HRP20151006T1 HRP20151006T1 HRP20151006TT HRP20151006T HRP20151006T1 HR P20151006 T1 HRP20151006 T1 HR P20151006T1 HR P20151006T T HRP20151006T T HR P20151006TT HR P20151006 T HRP20151006 T HR P20151006T HR P20151006 T1 HRP20151006 T1 HR P20151006T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- daptz
- crystalline
- stable
- reduced form
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims 2
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 238000002372 labelling Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- LZILOGCFZJDPTG-UHFFFAOYSA-N 10h-phenothiazine-3,7-diamine Chemical compound C1=C(N)C=C2SC3=CC(N)=CC=C3NC2=C1 LZILOGCFZJDPTG-UHFFFAOYSA-N 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002027 Amyotrophy Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010013142 Disinhibition Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000005135 methemoglobinemia Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (16)
1. Spoj 3,7-diaminofenotiazina (DAPTZ-spoj) u stabilnom, kristalnom, reduciranom obliku, naznačen time, da se upotrebljava kod pacijenta u postupku liječenja ili profilakse kognitivnog poremećaja ili CNS-poremećaja, pri čemu je spomenuti poremećaj onaj koji je osjetljiv na liječenje pomoću navedenog DAPTZ-spoja,
dok taj postupak obuhvaća oralno davanje navedenom pacijentu jedinične doze koja sadrži spomenuti DAPTZ-spoj u stabilnom, kristalnom reduciranom obliku kao djelatni sastojak,
kada je pacijent onaj kojemu je utvrđeno da pati od hematološkog poremećaja, pri čemu bi se posljedice tog hematološkog poremećaja inače mogle pogoršati pomoću DAPTZ- spoja.
2. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 1, naznačen time, da jedinična doza je formulacija s odgođenim oslobađanjem reduciranog DAPTZ-spoja na 100-1000 mg.
3. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 2, naznačen time, da formulacija s odgođenim oslobađanjem otpušta manje od <50% u periodu od jednog sata, dva sata, tri sata, četiri sata, pet sati, šest sati, sedam sati ili osam sati.
4. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da formulacija s odgođenim oslobađanjem ne sadrži više od 5 masenih % oksidiranog DAPTZ-spoja.
5. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da kognitivni poremećaj ili CNS poremećaj je tauopatija.
6. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da kognitivni poremećaj ili CNS poremećaj je odabran od sljedećih:
(i) Alzheimerova bolest, Pickova bolest, progresivna supranuklearna palsija (PSP), fronto-temporalna demencija, fronto-temporalna demencija s parkinsonizmom povezanim s kromosomom 17, mješavina disinhibicije, demencije, parkinsonizma i amiotrofije, palido-ponto-nigralna degeneracija, sindrom Guam-ALS, palido- nigro-luizijanska degeneracija, kortiko-bazalna degeneracija, ili
(ii) blago kognitivno oštećenje, ili
(iii) sinukleinopatija koja je opcijski Parkinsonova bolest, demencija s Lewyjevim tijelima, višestruka sustavna atrofija, parkinsonizam izazvan lijekovima, ili potpuni autonomni zastoj (PAF).
7. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da pacijent je onaj za kojega se zna da boluje od: hemoglobinopatije koja je opcijski bolest srpastih stanica, talasemija ili metemoglobinemija; anemije koja je opcijski hemolitička anemija; hematološke malignosti koja je opcijski limfom, mijelom, plazmacitom ili leukemija; koagulopatije koja je opcijski hemofilija.
8. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 7, naznačen time, da pacijent je star preko 70 godina i izložen je stanju anemije koja je povezana sa starošću, te koja je opcijski mijeloidna displazija.
9. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je navedeni DAPTZ-spoj odabran od spojeva sa sljedećom formulom, te njegove farmaceutski prihvatljive soli, njegovi solvati i hidrati:
[image]
gdje:
svaki od R1 i R9 je neovisno odabran od sljedećih: -H, C1-4-alkil, C2-4-alkenil i halogenirani C1-4-alkil;
svaki od R3NA i R3NB je neovisno odabran od sljedećih: -H, C1-4-alkil, C2-4-alkenil i halogenirani C1-4-alkil;
svaki od R/NA i R7NB je neovisno odabran od sljedećih: -H, C1-4-alkil, C2-4-alkenil i halogenirani C1-4-alkil;
svaki od HX1 i HX2 je neovisno protična kiselina.
10. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 9, naznačen time, da svaki od R1 i R9 je neovisno -H.
11. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 9 ili zahtjevu 10, naznačen time, da svaki od R3NA i R3NB i R7NA i R7NB je neovisno -Me, -Et, -nPr, -nBu, -CH2-CH=CH2 ili -CF3.
12. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema bilo kojem od zahtjeva 9 do 11, naznačen time, da svaka od skupina -N(R3NA)(R3NB) i -N(R7NA)(R7NB) je -NMe2.
13. Uporaba DAPTZ-spoja u stabilnom, kristalnom, reduciranom obliku prema bilo kojem od zahtjeva 1 do 12, naznačena time, da je za proizvodnju jedinične doze lijeka za uporabu u postupku koji je definiran prema bilo kojem od zahtjeva 1 do 12.
14. Spoj 3,7-diaminofenotiazina (DAPTZ-spoj) u stabilnom, kristalnom, reduciranom obliku, naznačen time, da se upotrebljava u postupku označavanja agregiranog proteina bolesti povezane s neurodegenerativnim poremećajem u mozgu pacijenta, kako bi se navedeni poremećaj prognozirao ili dijagnosticirao, kada je taj agregirani protein bolesti, onaj koji je prijemčiv na označavanje pomoću navedenog DAPTZ-spoja, dok taj postupak obuhvaća oralno davanje navedenom pacijentu jedinične doze koja sadrži spomenuti DAPTZ-spoj kao djelatno sredstvo za označavanje, pri čemu je taj pacijent onaj kojemu je utvrđeno da boluje od hematološkog poremećaja, gdje bi se posljedice tog hematološkog poremećaja inače mogle pogoršati pomoću DAPTZ-spoja.
15. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 14, naznačen time, da je DAPTZ-spoj definiran zahtjevom prema bilo kojem od patentnih zahtjeva 9 do 12.
16. DAPTZ-spoj u stabilnom, kristalnom, reduciranom obliku za uporabu prema zahtjevu 14 ili zahtjevu 15, naznačen time, da DAPTZ-spoj uključuje, konjugiran je na, kelatiran je s, ili je na neki drugi način povezan s jednom ili više oznaka koje se mogu otkrivati, a koje su opcijski odabrane od sljedećih: izotopi, radioizotopi, atomi koji emitiraju pozitrone, oznake magnetske rezonancije, pigmenti, fluorescentni markeri, antigenske skupine ili terapeutski dijelovi molekula.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96054407P | 2007-10-03 | 2007-10-03 | |
| EP08806465.4A EP2205245B1 (en) | 2007-10-03 | 2008-10-01 | Therapeutic use of diaminophenothiazines |
| PCT/GB2008/003315 WO2009044127A1 (en) | 2007-10-03 | 2008-10-01 | Therapeutic use of diaminophenothiazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151006T1 true HRP20151006T1 (hr) | 2015-10-23 |
Family
ID=40220337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151006TT HRP20151006T1 (hr) | 2007-10-03 | 2015-09-23 | Terapeutska uporaba diaminofenotiazina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9149481B2 (hr) |
| EP (2) | EP2205245B1 (hr) |
| JP (1) | JP5592261B2 (hr) |
| CN (1) | CN101883567B (hr) |
| AU (1) | AU2008306688B2 (hr) |
| BR (1) | BRPI0818182B1 (hr) |
| CA (2) | CA3027974C (hr) |
| DK (2) | DK2205245T3 (hr) |
| ES (2) | ES2701089T3 (hr) |
| HK (2) | HK1140675A1 (hr) |
| HR (1) | HRP20151006T1 (hr) |
| HU (1) | HUE025199T2 (hr) |
| MY (1) | MY161656A (hr) |
| PL (2) | PL2205245T3 (hr) |
| PT (2) | PT2205245E (hr) |
| SI (2) | SI2205245T1 (hr) |
| WO (1) | WO2009044127A1 (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| EP2205245B1 (en) * | 2007-10-03 | 2015-06-24 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| EP2585073B1 (en) | 2010-04-30 | 2016-04-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US9192611B2 (en) | 2010-11-30 | 2015-11-24 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
| WO2012145567A1 (en) | 2011-04-20 | 2012-10-26 | Prosetta Antiviral Inc. | Antiviral compounds |
| US20130315825A1 (en) * | 2012-05-03 | 2013-11-28 | Washington University | Tricyclic heteroaromatic compounds as alpha-synuclein ligands |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| CN103923036B (zh) * | 2014-04-24 | 2015-09-16 | 山东理工大学 | 一种棒状亚甲基蓝晶体的制备方法 |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| KR102475825B1 (ko) * | 2016-07-25 | 2022-12-08 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| KR20210038586A (ko) | 2018-07-26 | 2021-04-07 | 위스타 레보레이토리스 리미티드 | 집단에서 디아미노페노티아진(diaminophenothiazines)의 최적 투여량 |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN111956245A (zh) * | 2020-08-27 | 2020-11-20 | 复旦大学附属肿瘤医院 | 术后认知功能障碍预防评估方法，系统和装置 |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
| WO2024163665A1 (en) * | 2023-01-31 | 2024-08-08 | Unlearn.AI, Inc. | Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US7410965B2 (en) * | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| US7790881B2 (en) * | 2004-09-23 | 2010-09-07 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| US20070116757A1 (en) | 2005-11-08 | 2007-05-24 | Collegium Pharmaceutical, Inc. | Methylene Blue Derivatives |
| ES2349322T7 (es) * | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| US8263589B2 (en) * | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
| CN101511803B (zh) * | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| PL2167095T3 (pl) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| EP2205245B1 (en) * | 2007-10-03 | 2015-06-24 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
-
2008
- 2008-10-01 EP EP08806465.4A patent/EP2205245B1/en active Active
- 2008-10-01 SI SI200831497T patent/SI2205245T1/sl unknown
- 2008-10-01 EP EP15161198.5A patent/EP2954932B1/en active Active
- 2008-10-01 DK DK08806465.4T patent/DK2205245T3/en active
- 2008-10-01 JP JP2010527519A patent/JP5592261B2/ja active Active
- 2008-10-01 US US12/681,511 patent/US9149481B2/en active Active
- 2008-10-01 WO PCT/GB2008/003315 patent/WO2009044127A1/en active Application Filing
- 2008-10-01 PL PL08806465T patent/PL2205245T3/pl unknown
- 2008-10-01 CA CA3027974A patent/CA3027974C/en active Active
- 2008-10-01 HU HUE08806465A patent/HUE025199T2/en unknown
- 2008-10-01 PT PT88064654T patent/PT2205245E/pt unknown
- 2008-10-01 DK DK15161198.5T patent/DK2954932T3/en active
- 2008-10-01 CN CN2008801190788A patent/CN101883567B/zh active Active
- 2008-10-01 AU AU2008306688A patent/AU2008306688B2/en active Active
- 2008-10-01 ES ES15161198T patent/ES2701089T3/es active Active
- 2008-10-01 ES ES08806465.4T patent/ES2546819T3/es active Active
- 2008-10-01 PT PT15161198T patent/PT2954932T/pt unknown
- 2008-10-01 MY MYPI2010001396A patent/MY161656A/en unknown
- 2008-10-01 CA CA2701075A patent/CA2701075C/en active Active
- 2008-10-01 BR BRPI0818182-9A patent/BRPI0818182B1/pt active IP Right Grant
- 2008-10-01 SI SI200832022T patent/SI2954932T1/sl unknown
- 2008-10-01 PL PL15161198T patent/PL2954932T3/pl unknown
-
2010
- 2010-07-20 HK HK10107014.5A patent/HK1140675A1/xx unknown
-
2015
- 2015-09-23 HR HRP20151006TT patent/HRP20151006T1/hr unknown
- 2015-09-25 US US14/866,035 patent/US10188658B2/en active Active
- 2015-12-31 HK HK15112907.0A patent/HK1211889A1/xx unknown
-
2019
- 2019-01-15 US US16/248,746 patent/US20190151329A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151006T1 (hr) | Terapeutska uporaba diaminofenotiazina | |
| HRP20180204T1 (hr) | Spojevi tioninija i njihova primjena | |
| JP2010540606A5 (hr) | ||
| IT1266565B1 (it) | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. | |
| SI2004155T1 (en) | Protein aggregation inhibitors | |
| DK1205190T3 (da) | Stabile medicinalsammensætninger til oral administration og med anvendelse af ferrioxider | |
| DE69212882D1 (de) | Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung | |
| ES2314593T3 (es) | Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion y composiciones farmaceuticas que la contienen. | |
| KR102035442B1 (ko) | 의약으로서 3,6-이중치환된 크산틸륨 염 | |
| ATE156835T1 (de) | Neue 11-benzaldoximestradien-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| YU9194A (sh) | Derivati pipolo-piridina | |
| TR200001810A2 (tr) | Hemen Eriyen Oral Dozaj Formülasyonu. | |
| PT2057136E (pt) | Processos de síntese e/ou purificação de compostos diaminofenotiazínio | |
| EP0648779A3 (de) | Neue 11-Benzaldoxim-17beta methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel. | |
| BR9510410A (pt) | Composto, composição farmacêutica ou veterinária, processo para produzir o composto e uso do composto | |
| ATE87313T1 (de) | Cephemverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
| DE69736890D1 (de) | Kondensierte heterozyklische verbindungen und ihre pharmazeutische anwendung | |
| ZA814845B (en) | Substituted pyrimidin-2-ones, the salts thereof, process for their preparation, pharmaceutical compositions containing them and a method therefor | |
| MY138865A (en) | New tricyclic azepine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| ZA933455B (en) | Thiochroman compounds, processes for the preparation thereof and pharmaceutical compositions containing them | |
| HRP20100622T1 (hr) | Novi derivati cikloalkiliranog benzotiadizina, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| ATE330956T1 (de) | Bizyklisch substituierte 4- aminopyridopyrimidinderivate | |
| ATE229513T1 (de) | Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen | |
| AU668398B2 (en) | New aminoalkylchromones, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| DK527483A (da) | Fremgangsmaade til fremstilling af benzazepinderivater |